01.
The Capital Opportunity
A $331B SME financing gap across Sub-Saharan Africa, with 51% of the continent’s 44 million formal businesses lacking the growth capital they need.
Pan-African Growth Capital
High-growth African SMEs shaping Africa’s future. Systemic impacts and returns at scale.
ThirdWay Capital is an investment company backing Africa's most compelling scale-ready businesses. We target sectors that will drive this continent’s capacity and growth. Our first-in capital and expert business support sets our companies on a success-path for growth that drives systems change.
- $0M
Target Fund Size
- 0.5M
Target Number of Individuals Gaining Economic Agency
- 0
Investment Regions
- 0
Investing Since
Africa's growth-stage businesses need a different kind of capital partner.
We occupy an underserved space full of companies demonstrating the potential to shape Africa at a systems level. They have proven their model is ready for the capital and expert systems-change guidance that will enable it to scale optimally. ThirdWay Capital sets Africa’s high potential early-stage companies on the path to success, with capital to pursue scale, tools for effective growth strategy and execution, and hands-on operational partnership for the long-haul to market leadership.
02.
The ThirdWay Position
We invest $300K–$1M in businesses ready to scale — gaining access to exceptional deals with systems-level potential, not only in our three target regions, but across the continent.
03.
The Returns Thesis
Businesses solving genuine African and global market needs, supported by the ThirdWay Performance Suite, deliver systemic impact and commercial returns together, at scale.
Capital is just the beginning
Capital is start.
The rest is an adventure together.
We partner with companies in the long-play adventure that gets them to regional and international scale and growth. We invest in Sub-Saharan Africa, with a particular focus on Ghana, South Africa and Kenya.
01.
Catalytic Capital
$300K–$1M initial tickets in growth-ready SMEs operating in value chains central to Africa’s social and economic transformation.
02.
Operational Partnership
Board representation, strategy reviews, and the ThirdWay Performance Suite — built on decades of management consulting and leadership experience across four continents.
03.
Social Capital
Access to networks and technical expertise. Credible third-party partnership in complex negotiations. Our global network spanning three continents opens doors that capital alone cannot open.
04.
Follow-on Capital
As portfolio companies scale, we support access to follow-on investment — from ThirdWay Capital (up to $2M) and from third-party financiers — bridging the gap to larger institutional capital.
portfolio
Our thesis in action.
Our founders have built companies that are creating measurable structural and economic impact in sectors central to Africa’s future while delivering excellent commercial performance.
Fairafric
Fairafric is a farm-to-table organic chocolate company successfully distributing premium organic chocolate in Europe and positioned to enter other African and North American markets.
Ethical Apparel Africa
Ethical Apparel Africa is a sourcing, manufacturing and export business positioned to scale as a major driver in a forecast 3X growth (by 2035) in Ghanaian apparel exports to American and European markets.
Agro Kings
Ghana’s 2nd largest rice producer (2024), displacing a $600M annual import market with locally grown rice — led by a predominantly female farm mechanisation team, and working extensively with small hold farmers.
Rainbow Mobile Networks
Rainbow Mobile Networks Ltd. is a communication technology solution provider who provide communication network solutions for the unserved and underserved.
Ditto Labs
Ditto is a B2B manufacturer of dairy alternative products with the mission to make dairy alternatives that are affordable, accessible, tasty and packaged to international standards locally.
Fluorobiotech
Patented recombinant protein platform enabling affordable local vaccine production — 8× faster and 30%+ cheaper. Aligned with WHO’s 60% African vaccine production target by 2040.
FROM OUR PORTFOLIO FOUNDERS